Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
3 offices
Technology Company

We have observed 25 EP applications Michael Antony Reed has served for within the last five+ years. (We consider all applications which have an EP A1 or A2 publication dated after November 16, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12714282

DIHYDROPYRROLO PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS

IPC classification:
A61K 31/519, C07D 487/04, A61P 37/00, A61P 35/00
Applicant:
Cellzome Ltd
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12826459

FATTY ACID SYNTHASE INHIBITORS

IPC classification:
A01N 43/42
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
PATENT GRANTED
EP12739192

COMBINATIONS

IPC classification:
A61P 35/00, A61K 45/06, A61K 31/337, A61K 31/4439, A61K 31/506
Applicant:
GlaxoSmithKline Intellectual Property Limited
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
APPLICATION WITHDRAWN
EP12843835

NEW COMPOUNDS

IPC classification:
A61K 31/52
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12842775

CHEMICAL COMPOUNDS

IPC classification:
A61K 31/52, C07D 473/34
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
EXAMINATION IN PROGRESS
EP12845460

METHOD OF TREATMENT

IPC classification:
C12N 9/10, A61P 37/00
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
PATENT GRANTED
EP12832131

AZAINDAZOLES

IPC classification:
C07D 401/00
Applicant:
GlaxoSmithKline LLC
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
PATENT GRANTED
EP13704029

METHOD OF TREATING CANCER

IPC classification:
C12Q 1/68
Applicant:
Novartis AG
Agent:
Markus Gruber, Novartis Pharma AG
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12804047

METHOD OF ADMINISTRATION AND TREATMENT

IPC classification:
A61K 38/00, A61K 31/535, A61K 31/4439, G01N 33/574, C12N 15/113
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13717779

TREATMENT METHOD FOR STEROID RESPONSIVE DERMATOSES

IPC classification:
A61K 45/06, A61K 31/4155, A61K 9/00, A61P 17/06, A61P 17/00
Applicant:
Novartis AG
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Sewkian Rudge, Novartis Pharma AG
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP14196983

Pyridazine-dione N-substituted glycine derivatives as HIF hydroxylase inhibitors

IPC classification:
A61K 31/50, C07D 237/24, A61P 7/06
Applicant:
GlaxoSmithKline LLC
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
PATENT GRANTED
EP13845429

COMBINATIONS

IPC classification:
A61K 31/519, A61K 31/44, C07D 487/04
Applicant:
GlaxoSmithKline LLC
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP12733916

COMBINATION

IPC classification:
A61P 35/00, A61K 45/06, A61K 31/69, A61K 31/4155, A01N 43/56
Applicant:
Novartis AG
Applicant:
GlaxoSmithKline LLC
Agent:
Michael Antony Reed, GlaxoSmithKline
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13870106

ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS

IPC classification:
C07D 213/56
Applicant:
GlaxoSmithKline LLC
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
GRANT OF PATENT INTENDED
EP13864107

COMBINATION

IPC classification:
A61K 31/496
Applicant:
GlaxoSmithKline LLC
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
GRANT OF PATENT INTENDED
EP14702083

FATTY ACID SYNTHASE INHIBITORS

IPC classification:
A61K 31/41, C07D 401/14, A61P 35/00
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
The patent has been granted
EP14702081

COMBINATION

IPC classification:
A61K 31/5377, A61K 31/4375, A61P 35/00
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
GRANT OF PATENT INTENDED
EP14727619

ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS

IPC classification:
A61P 35/00, A61K 31/4427, A61K 31/381, C07D 409/14, C07D 409/12, C07D 401/12, C07D 413/14, C07D 405/14
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP14732021

ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS

IPC classification:
A61P 35/00, A61K 31/4353, C07D 471/04
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
EXAMINATION IN PROGRESS
EP14741958

ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS

IPC classification:
C07D 409/12, A61P 35/00, A61K 31/4436, C07D 409/14
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
PATENT GRANTED
EP15714943

CHEMICAL COMPOUNDS ACTING AS PERK INHIBITORS

IPC classification:
A61P 25/28, A61P 25/16, A61P 35/00, C07D 495/04, A61K 31/519, A61K 31/4365, C07D 487/04
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP15767475

NOVEL COMPOUNDS

IPC classification:
A61K 31/4375, A61P 11/00, C07D 471/04
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
Request for examination was made
EP15767479

NOVEL COMPOUNDS

IPC classification:
A61K 31/4375, A61P 11/00, C07D 471/04
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
Request for examination was made
EP15767476

NOVEL COMPOUNDS

IPC classification:
A61K 31/4375, A61P 11/00, C07D 471/04
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
The patent has been granted
EP15767478

NAPHTHYRIDINE DERIVATIVES AS ALPHA V BETA 6 INTEGRIN ANTAGONISTS FOR THE TREATMENT OF E.G. FIBROTIC DISEASES

IPC classification:
A61K 31/4375, A61P 11/00, C07D 471/04
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
Request for examination was made

Please Sign in to use this feature